8-K
filed September 25, 2023, 7:59 PM ET
ticker VVOS
CIK 0001716166
other material
confidence high
sentiment neutral
materiality 0.55
Vivos Therapeutics shareholders approve reverse stock split and increase in stock plan shares
Vivos Therapeutics, Inc.
- Approved amendment to 2019 Stock Plan to increase authorized shares by 2,000,000 to 4,366,667 total.
- Approved reverse stock split at ratio between 1:10 and 1:30, with Board discretion on exact ratio.
- Elected six directors: Green, Krammer, Lindsay, Sokolow, Thompson, Huntsman for one-year terms.
- Ratified Moss Adams LLP as independent auditor for fiscal year ending Dec 31, 2023.
- Reverse split authorized by 12.7M votes for vs 5.7M against; stock plan approved by 6.0M for vs 5.4M against.
Key facts
Extracted from this filing and checked against the source text.
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Vivos Therapeutics, Inc. shareholders approved Amendment to Amended and Restated 2019 Stock Option and Stock Issuance Plan to increase authorized shares by 2,000,000 at the 2023-09-22 meeting.
- Proposal
- equity plan
- Outcome
- passed
- Meeting
- 2023-09-22
Exact text from the filing
Proposal No. 1 – Amendment to 2019 Plan An amendment to the Company’s 2019 Plan to increase the number of shares of Company common stock authorized to be issued pursuant to the 2019 Plan by 2,000,000 shares from an aggregate of 2,366,667 shares to an aggregate of 4,366,667 shares was approved.
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Vivos Therapeutics, Inc. shareholders approved Ratification of appointment of Moss Adams LLP as independent registered public accounting firm for fiscal year ending December 31, 2023 at the 2023-09-22 meeting.
- Proposal
- auditor ratification
- Outcome
- passed
- Meeting
- 2023-09-22
Exact text from the filing
Proposal No. 3 – Ratification of the appointment of independent registered public accounting firm Appointment by the Company’s audit committee of Moss Adams LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023 was ratified.
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Vivos Therapeutics, Inc. shareholders approved Election of six directors for a one-year term at the 2023-09-22 meeting.
- Proposal
- director election
- Outcome
- passed
- Meeting
- 2023-09-22
Exact text from the filing
Proposal No. 2 – Election of Directors Dr. Ralph Green, Anja Krammer, Mark Lindsay, Leonard Sokolow, Dr. Matthew Thompson and R. Kirk Huntsman were each elected as a director to serve for a one-year term that expires at the 2024 annual meeting of stockholders or until a successor is elected and qualified or until her or his earlier death, incapacity, removal or resignation.
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Vivos Therapeutics, Inc. shareholders approved Amendment to Certificate of Incorporation to effect a reverse stock split at a ratio of between one-for-ten and one-for-thirty, with ratio to be determined by Board at the 2023-09-22 meeting.
- Proposal
- reverse split
- Outcome
- passed
- Meeting
- 2023-09-22
Exact text from the filing
Proposal No. 4 – Approval of Reverse Stock Split An amendment to the Company’s Certificate of Incorporation, as amended to effect a Reverse Split at a ratio of between one-for-ten and one-for-thirty, with such ratio to be determined at the sole discretion of the Company’s Board of Directors, was approved.
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.